With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.171504-98-6,Methyl 1,4-Bis(Boc)-2-piperazinecarboxylate,as a common compound, the synthetic route is as follows.
(B) 1,4-Di-(N-tert-Butoxycarbonyl)-2-Piperazinecarboxylic Acid A solution of 1 N sodium hydroxide (1.2 mL) was added to a solution methyl 1,4-di-(N-tert-butoxycarbonyl)-2-piperazinecarboxylate (A, 290 mg) in methanol (10 mL). The mixture was stirred at room temperature for 12 hr and evaporated in vacuo. The residue was diluted with water and washed with ether. The aqueous layer was acidified with 10% citric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and evaporated in vacuo to give the title compound (230 mg) as a colorless foam: 1H NMR (400 MHz, CDCl3) delta 1.44 (s,18H) and 4.56-4.75 (m, 1H)., 171504-98-6
The synthetic route of 171504-98-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Microcide Pharmaceuticals, Inc.; US6399629; (2002); B1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics